未登录

T

Tom Bäck

university of gothenburg

H指数:30

被引数:2,558

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Pretargeted Alpha Therapy of Disseminated Cancer Combining Click Chemistry and Astatine-211

PHARMACEUTICALS

IF4.8

2023-04-1511

OAAI

Astatine-211 based radionuclide therapy: Current clinical trial landscape

FRONTIERS IN MEDICINE

IF3

2023-01-0638

OAAI

Estimating the Risk for Secondary Cancer After Targeted α-Therapy with 211At Intraperitoneal Radioimmunotherapy

JOURNAL OF NUCLEAR MEDICINE

IF9.1

2022-07-074

OAAI

Radium-223-Induced Bystander Effects Cause DNA Damage and Apoptosis in Disseminated Tumor Cells in Bone Marrow

MOLECULAR CANCER RESEARCH

IF4.7

2021-05-2616

OA

Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors

EJNMMI RESEARCH

IF3

2020-02-1120

OAAI

Dose-Dependent Growth Delay of Breast Cancer Xenografts in the Bone Marrow of Mice Treated with 223Ra: The Role of Bystander Effects and Their Potential for Therapy

JOURNAL OF NUCLEAR MEDICINE

IF9.1

2019-09-1336

OAAI

Intraperitoneal α-Emitting Radioimmunotherapy with 211At in Relapsed Ovarian Cancer: Long-Term Follow-up with Individual Absorbed Dose Estimations

JOURNAL OF NUCLEAR MEDICINE

IF9.1

2019-01-2548

OAAI

Model of Intraperitoneal Targeted α-Particle Therapy Shows That Posttherapy Cold-Antibody Boost Enhances Microtumor Radiation Dose and Treatable Tumor Sizes

JOURNAL OF NUCLEAR MEDICINE

IF9.1

2017-11-248

OAAI

Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer model

在具有免疫能力的转基因乳腺癌模型中，α 发射器标记的anti-PD-L1抗体的药代动力学，微尺度分布和剂量学

EJNMMI RESEARCH

IF3

2017-07-1837

OAAI

Formation of DNA double-strand breaks in colon tumors after targeted alpha therapy with 211At-mAb

CANCER RESEARCH

IF16.6

2017-07-010

PRE

Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b

IF3.4

2017-05-0231

OAAI

Therapeutic efficacy of α-radioimmunotherapy with different activity levels of the 213Bi-labeled monoclonal antibody MX35 in an ovarian cancer model

EJNMMI RESEARCH

IF3

2017-04-2418

OAAI

Cure of Human Ovarian Carcinoma Solid Xenografts by Fractionated α-Radioimmunotherapy with 211At-MX35-F(ab')2: Influence of Absorbed Tumor Dose and Effect on Long-Term Survival

JOURNAL OF NUCLEAR MEDICINE

IF9.1

2016-09-2920

OAAI

Synthesis and Evaluation of Astatinated N-[2-(Maleimido)ethyl]-3-(trimethylstannyl)benzamide Immunoconjugates

BIOCONJUGATE CHEMISTRY

IF3.9

2016-01-2922

PREAI

Biokinetic Modeling and Dosimetry for Optimizing Intraperitoneal Radioimmunotherapy of Ovarian Cancer Microtumors

JOURNAL OF NUCLEAR MEDICINE

IF9.1

2016-01-1419

OAAI

Small Scale Renal Dosimetry for Alpha Particle Radiopharmaceutical Therapy of Metastatic Breast Cancer With 225Ac-7.16.4

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

IF6.5

2015-11-015

PREAI

Absorbed Doses and Risk Estimates of 211At-MX35 F(ab′)2 in Intraperitoneal Therapy of Ovarian Cancer Patients

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

IF6.5

2015-11-0143

PREAI

Automated astatination of biomolecules - a stepping stone towards multicenter clinical trials

SCIENTIFIC REPORTS

IF3.9

2015-07-1437

OAAI

Ex Vivo Activity Quantification in Micrometastases at the Cellular Scale Using the α-Camera Technique

JOURNAL OF NUCLEAR MEDICINE

IF9.1

2013-06-1224

OAAI

Successful radioimmunotherapy of established syngeneic rat colon carcinoma with 211 At-mAb

EJNMMI RESEARCH

IF3

2013-01-018

OAAI